What are the first‑line and subsequent medication options for adult functional constipation, including indications, side effects, and supporting evidence?

Pharmacological Management of Chronic Constipation

Start with polyethylene glycol (PEG) as first-line therapy for chronic idiopathic constipation in adults, with strong evidence supporting its efficacy and durability over 6 months. 1

First-Line Treatment Algorithm

Initial Therapy: Osmotic Laxatives

Polyethylene glycol (PEG) receives a strong recommendation with moderate certainty of evidence as the primary treatment 1. This is your go-to agent because:

• Proven durable response over 6 months
• Well-tolerated with predictable side effects
• Can be combined with fiber supplements for mild constipation
• Side effects: abdominal distension, loose stool, flatulence, nausea 1

Fiber supplements (specifically psyllium) can be used as first-line therapy, particularly in patients with low dietary fiber intake, but receive only a conditional recommendation with low certainty 1. Key points:

• Only psyllium has demonstrated effectiveness among fiber supplements
• Encourage adequate hydration
• Side effect: flatulence is common and may limit use 1
• Best for mild constipation or as adjunct to PEG

Magnesium oxide is an alternative osmotic laxative with a conditional recommendation and very low certainty of evidence 1:

• Start at lower dose and titrate up
• Critical caveat: Avoid in renal insufficiency due to hypermagnesemia risk 1
• Trials only conducted for 4 weeks, though longer use is probably appropriate

Rescue/Short-Term Therapy: Stimulant Laxatives

Bisacodyl or sodium picosulphate receive a strong recommendation with moderate certainty for short-term use (≤4 weeks) or rescue therapy 1. This is your breakthrough medication:

• Excellent for occasional use or rescue therapy combined with other agents
• Side effects: abdominal pain, cramping, diarrhea 1
• Start at lower dose and titrate as tolerated
• While long-term use is probably appropriate, data on tolerance and side effects beyond 4 weeks are limited 1

Senna receives a conditional recommendation with low certainty 1:

• Trial doses in studies were higher than typical clinical practice—start low and increase if no response
• Side effects: abdominal pain and cramping, especially at higher doses 1
• Limited to 4-week trial data, though longer use is probably acceptable

Lactulose is reserved for patients who fail or are intolerant to other OTC therapies, with a conditional recommendation and very low certainty 1:

• Major limitation: Bloating and flatulence are dose-dependent and common, often limiting clinical use 1

Second-Line Treatment: Prescription Agents for OTC Failures

When patients don't respond to over-the-counter agents, you have three classes with strong recommendations and moderate certainty of evidence:

Guanylate Cyclase-C Agonists (Secretagogues)

Linaclotide 1:

• Strong recommendation, moderate certainty
• Use as replacement or adjunct to OTC agents
• Studied for 12 weeks; no drug label time limit
• Side effect: diarrhea leading to discontinuation in some patients

Plecanatide 1:

• Strong recommendation, moderate certainty
• Same profile as linaclotide: replacement or adjunct option
• 12-week trial data; no label time limit
• Side effect: diarrhea causing discontinuation

Prokinetic Agent

Prucalopride 1:

• Strong recommendation, moderate certainty
• 5-HT4 receptor agonist promoting colonic motility
• Studied for 4-24 weeks; no label time limit
• Use as replacement or adjunct to OTC agents
• Side effects: headache, abdominal pain, nausea, diarrhea 1

Chloride Channel Activator

Lubiprostone 1:

• Conditional recommendation, low certainty (weaker evidence than the above three)
• Use as replacement or adjunct to OTC agents
• 4-week trial data; no label time limit
• Side effect: nausea (dose-dependent; reduced when taken with food and water) 1

Clinical Decision-Making Framework

Step 1: Start PEG for most patients. Consider adding psyllium if dietary fiber intake is low and constipation is mild.

Step 2: Add bisacodyl or sodium picosulphate for rescue therapy or short-term use (≤4 weeks) if PEG alone is insufficient.

Step 3: If no response to OTC agents after adequate trial, escalate to prescription agents. Choose based on:

• Linaclotide, plecanatide, or prucalopride are your strongest options (all have strong recommendations with moderate certainty)
• Lubiprostone is a reasonable alternative but has weaker evidence
• All can be used as replacement OR adjunct to OTC therapy

Step 4: Consider combination therapy—prescription agents can be added to ongoing OTC regimens rather than replacing them entirely.

Important Caveats and Pitfalls

Avoid these common mistakes:

1. Don't use magnesium oxide in renal insufficiency—risk of hypermagnesemia is real and dangerous 1

2. Don't dismiss stimulant laxatives as "unsafe" for long-term use—while data beyond 4 weeks are limited, the guideline panel notes long-term use is probably appropriate 1. The old teaching about colonic damage from chronic stimulant use is not evidence-based.

3. Don't forget to take lubiprostone with food and water—this significantly reduces nausea, the main limiting side effect 1

4. Don't start senna at trial doses—studies used higher doses than typical practice; start low to avoid cramping 1

5. Don't overlook diarrhea as a discontinuation factor—with linaclotide and plecanatide, diarrhea can be severe enough to stop treatment 1

6. Don't forget adequate hydration with fiber—this is essential for efficacy and preventing worsening symptoms 1

Strength of Evidence Summary

The 2023 AGA-ACG guideline 1 provides the most comprehensive and recent evidence-based recommendations:

• Strong recommendations (moderate certainty): PEG, bisacodyl/sodium picosulphate, linaclotide, plecanatide, prucalopride
• Conditional recommendations (low to very low certainty): Fiber supplements, magnesium oxide, lactulose, senna, lubiprostone

The European guidelines 2 from 2020 align with these recommendations, particularly emphasizing PEG, prucalopride, and secretagogues as high-level evidence treatments.

Practical Implementation

Cost and access considerations: Most prescription agents (linaclotide, plecanatide, prucalopride, lubiprostone) are brand-name only, requiring prior authorization and potentially significant out-of-pocket costs 1. Start with OTC options (PEG, fiber, stimulant laxatives) which are readily available and affordable.

Shared decision-making: Discuss side effect profiles with patients—some prefer to tolerate bloating/flatulence (fiber, lactulose) while others find diarrhea (secretagogues) or nausea (lubiprostone) more problematic.

Duration: While most trials were 4-12 weeks, drug labels don't provide time limits for prescription agents, and long-term use is appropriate for chronic conditions 1.